Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients
Unicycive Therapeutics, Inc. (NASDAQ: UNCY ), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for oxyl